Staging Multifocal Breast Cancer: Use the Largest Tumor Only
Yes, in multifocal breast cancer, you stage by the largest tumor dimension only, not by summing all foci. According to established ESMO guidelines, the T stage is based exclusively on the size of the largest tumor focus, with the presence of multiple foci documented using the modifier '(m)' 1.
The Standard Approach
The TNM staging system is unequivocal on this point:
- Measure only the largest single tumor focus for T-stage determination
- Document multiplicity using the '(m)' modifier (e.g., pT2(m))
- Record the sizes of smaller foci separately in the pathology report, but these do not influence the T category 2, 1, 2
The guidelines explicitly state: "Multiple simultaneous ipsilateral primary carcinomas are defined as infiltrating carcinomas in the same breast, which are grossly or macroscopically distinct and measurable. T stage is based only on the largest tumour. The presence and sizes of the smaller tumour(s) should be recorded using the '(m)' modifier" 1.
Why This Matters Clinically
This staging convention has important practical implications:
- Treatment planning relies on accurate T-stage assignment
- Prognostic assessment uses the established TNM framework
- Clinical trial enrollment requires standardized staging
- Communication between providers depends on consistent methodology
The Controversy: Does This Underestimate Risk?
There is legitimate debate about whether measuring only the largest focus adequately captures tumor burden in multifocal disease. Several research studies suggest that summing all tumor dimensions may better predict outcomes:
- A 2005 study found that using aggregate dimensions removed the excess node positivity seen in multifocal cancers when compared to unifocal disease 3
- A 2023 analysis showed that aggregate dimensions upstaged 63 patients and better predicted lymph node involvement 4
- A 2019 study demonstrated that upstaging based on summed diameters was an independent poor prognostic factor (HR 2.757) 5
However, a 2013 randomized trial analysis (NCIC CTG MA.5 and MA.12) found that the current method of T-staging using the largest dimension offered equivalent prognostic determination compared to summation methods 6. More recently, a 2024 study confirmed that T-max stage (largest tumor) remained an independent prognostic factor for overall survival 7.
Post-Neoadjuvant Therapy: A Special Case
After neoadjuvant chemotherapy, the same principle applies but with specific nuances:
- Measure the largest single focus of residual invasive tumor for ypT staging
- Use the '(m)' modifier to indicate multiple residual foci
- Do not include areas of fibrosis within the tumor bed in measurements 8
The BIG-NABCG collaboration guidelines note that while the largest contiguous focus (AJCC 7th edition recommendation) may result in artificial downstaging of scattered response patterns, this remains the standard approach 9.
Practical Algorithm for Staging
- Identify all tumor foci on imaging and pathology
- Measure the largest dimension of the single largest focus
- Assign T stage based on this measurement alone
- Document multiplicity with the '(m)' modifier
- Record all other foci sizes in the pathology report for completeness
- Consider total tumor burden when making treatment decisions, even though it doesn't change the formal stage
Common Pitfalls to Avoid
- Do not sum tumor dimensions for T-stage assignment—this is not the current standard
- Do not confuse multifocal with multicentric—both use the same staging principle (largest focus only)
- Do not measure intervening fibrosis in post-treatment specimens
- Do not forget the '(m)' modifier—it signals the presence of additional disease that may influence treatment decisions beyond stage alone
The key clinical takeaway: While the formal T stage uses only the largest tumor, the presence of multifocality (documented with the '(m)' modifier) should inform your overall treatment strategy, particularly regarding surgical approach and systemic therapy intensity.